| Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. | |
| | |
MedLine Citation:
|
PMID: 20071777 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Phosphatase inhibitor-1 (I-1) is a distal amplifier element of beta-adrenergic signaling that functions by preventing dephosphorylation of downstream targets. I-1 is downregulated in human failing hearts, while overexpression of a constitutively active mutant form (I-1c) reverses contractile dysfunction in mouse failing hearts, suggesting that I-1c may be a candidate for gene therapy. We generated mice with conditional cardiomyocyte-restricted expression of I-1c (referred to herein as dTGI-1c mice) on an I-1-deficient background. Young adult dTGI-1c mice exhibited enhanced cardiac contractility but exaggerated contractile dysfunction and ventricular dilation upon catecholamine infusion. Telemetric ECG recordings revealed typical catecholamine-induced ventricular tachycardia and sudden death. Doxycycline feeding switched off expression of cardiomyocyte-restricted I-1c and reversed all abnormalities. Hearts from dTGI-1c mice showed hyperphosphorylation of phospholamban and the ryanodine receptor, and this was associated with an increased number of catecholamine-induced Ca2+ sparks in isolated myocytes. Aged dTGI-1c mice spontaneously developed a cardiomyopathic phenotype. These data were confirmed in a second independent transgenic mouse line, expressing a full-length I-1 mutant that could not be phosphorylated and thereby inactivated by PKC-alpha (I-1S67A). In conclusion, conditional expression of I-1c or I-1S67A enhanced steady-state phosphorylation of 2 key Ca2+-regulating sarcoplasmic reticulum enzymes. This was associated with increased contractile function in young animals but also with arrhythmias and cardiomyopathy after adrenergic stress and with aging. These data should be considered in the development of novel therapies for heart failure. |
| | |
Authors:
|
Katrin Wittköpper; Larissa Fabritz; Stefan Neef; Katharina R Ort; Clemens Grefe; Bernhard Unsöld; Paulus Kirchhof; Lars S Maier; Gerd Hasenfuss; Dobromir Dobrev; Thomas Eschenhagen; Ali El-Armouche |
Related Documents
:
|
12355407 - Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. 16856597 - Myosin heavy chain composition of tongue muscle in microphthalmic (mi/mi) mice before a... 16734387 - Ubiquitin ligase cbl-b downregulates bone formation through suppression of igf-i signal... 14499647 - Tace is required for fetal murine cardiac development and modeling. 2801887 - Production of tumor necrosis factor-alpha and lymphotoxin by cells of hodgkin's neoplas... 16528007 - High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-01-11 |
Journal Detail:
|
Title: The Journal of clinical investigation Volume: 120 ISSN: 1558-8238 ISO Abbreviation: J. Clin. Invest. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-03 Completed Date: 2010-03-03 Revised Date: 2012-02-07 |
Medline Journal Info:
|
Nlm Unique ID: 7802877 Medline TA: J Clin Invest Country: United States |
Other Details:
|
Languages: eng Pagination: 617-26 Citation Subset: AIM; IM |
Affiliation:
|
Institute of Experimental and Clinical Pharmacology and Toxicology, Cardiovascular Research Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Agonists
/
pharmacology Aging / drug effects, physiology* Animals Calcium / metabolism Catecholamines / physiology* Crosses, Genetic Dopamine and cAMP-Regulated Phosphoprotein 32 / deficiency, genetics Doxycycline / pharmacology Heart Rate Intracellular Signaling Peptides and Proteins / pharmacology* Major Histocompatibility Complex / immunology Mice Mice, Inbred C57BL Mice, Knockout Models, Animal Myocardial Contraction / drug effects* Phosphorylation Ryanodine Receptor Calcium Release Channel / physiology |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Agonists; 0/Catecholamines; 0/Dopamine and cAMP-Regulated Phosphoprotein 32; 0/Intracellular Signaling Peptides and Proteins; 0/Ppp1r1b protein, mouse; 0/Ryanodine Receptor Calcium Release Channel; 0/protein phosphatase inhibitor-1; 564-25-0/Doxycycline; 7440-70-2/Calcium |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-i...
Next Document: Neural Wiskott-Aldrich syndrome protein modulates Wnt signaling and is required for hair follicle cy...